Q. Scientists from the Department of Atomic Energy (DAE) and Bengaluru-based IDRS Labs have collaborated to develop Aktocyte tablets for the treatment of which disease?
Answer:
Cancer
Notes: Scientists from the Department of Atomic Energy (DAE) and Bengaluru-based IDRS Labs have collaborated to develop Aktocyte tablets for the treatment of pelvic cancer. These tablets are designed to supplement cancer radiotherapy, functioning as a regenerative nutraceutical, immunomodulator, and antioxidant. The collaboration involves experts from the Bhabha Atomic Research Centre, Tata Memorial Hospital, and the Advanced Centre for Training Research and Education in Cancer, along with IDRS Labs. The primary aim of this collaborative effort is to minimize the side effects of radiotherapy, which often impact patients’ quality of life. Aktocyte tablets have multiple innovative functions, supporting natural healing processes, enhancing the immune response to cancer cells, and protecting healthy cells from damage during radiotherapy. Aktocyte has received approval from the Food Safety and Standards Authority of India (FSSAI), ensuring its safety and quality standards. This development revolutionizes pelvic cancer care, offering a promising solution with multifunctional properties and regulatory approval.